Intuitive Surgical Faces Challenges Amid ACA Subsidy Expiration

Intuitive Surgical reported a slowdown in U.S. procedure growth using its da Vinci surgical robots in the second quarter, partly due to the expiration of enhanced Affordable Care Act subsidies. These subsidies lapsed at the end of 2025, shifting patients to high-deductible insurance plans and reducing enrollment. Despite these challenges, Intuitive maintains its forecast for global da Vinci procedure growth at 13.5% to 15.5% by 2026.

CEO Dave Rosa noted a change in patient insurance coverage impacting the timing of medical care. This influenced a 12% dip in Intuitive’s share price. While U.S. growth in da Vinci system procedures slowed, robust system placements indicated continued demand for the da Vinci 5. Internationally, procedures rose by 20%, reflecting strong global uptake.

Ongoing Innovations and Market Strategy

Despite subsidy cuts, Citi Research analyst Joanne Wuensch pointed to ongoing global capital investments and pipeline advancements as positive signs. Intuitive continues to innovate, with several new technologies filed for FDA approval and regulatory clearance for the da Vinci 5 in India. The company faces competition from Medtronic and new entrants targeting ambulatory surgery centers, but it’s adapting by offering refurbished systems and extending instrument life cycles to reduce costs.

Investing in new market opportunities, Intuitive focuses on cardiac procedures and nipple-sparing mastectomies, sectors with strong growth potential. CFO Jamie Samath highlighted the development of specialized instruments and clinical evidence to support these areas. BTIG analyst Ryan Zimmerman remains confident in Intuitive’s position, anticipating growth in cardiac, gastrointestinal, and ASC settings as future expansion drivers.